AstraZeneca (LON:AZN) Stock Rating Reaffirmed by UBS Group

Share on StockTwits

AstraZeneca (LON:AZN)‘s stock had its “sell” rating restated by equities research analysts at UBS Group in a report issued on Wednesday, ThisIsMoney.Co.Uk reports. They presently have a GBX 5,700 ($74.48) target price on the biopharmaceutical company’s stock, up from their prior target price of GBX 5,400 ($70.56). UBS Group’s price target would suggest a potential downside of 21.16% from the stock’s current price.

A number of other equities analysts have also issued reports on the stock. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research report on Friday, July 26th. Barclays set a GBX 7,600 ($99.31) target price on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, August 9th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Friday, August 9th. Citigroup reiterated a “buy” rating and issued a GBX 7,000 ($91.47) target price on shares of AstraZeneca in a research report on Monday, May 13th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of “Hold” and an average price target of GBX 6,688.24 ($87.39).

Shares of AZN opened at GBX 7,230 ($94.47) on Wednesday. The firm has a 50-day moving average price of GBX 6,755.80 and a 200 day moving average price of GBX 6,227.49. The firm has a market capitalization of $94.85 billion and a PE ratio of 42.23. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 52-week low of GBX 5,312 ($69.41) and a 52-week high of GBX 7,349.30 ($96.03).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.